Optiscan Imaging has reported a strong December quarter marked by accelerating clinical progress, growing commercial traction ...
Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water ...
Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by ...
Cancer Dx Panel expansion and inVue Dx FNA cytology rollout advance veterinary cancer care, enabling comprehensive mast cell tumor testing for dogs.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced two major advancements in veterinary cancer diagnostics: the expansion of its IDEXX Cancer Dxtm ...
The Portable Payment Center is available now through InVue, resellers, and channel partners.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results